MEK inhibition depends on assay activation state
Biochemical assay · Recombinant Raf–MEK–ERK and preactivated MEK–ERK kinase assays [1]
JTP-74057 inhibited the coupled activation cascade more potently than preactivated MEK; direct Raf/MBP assays were negative. ATP-varied kinetics supported ATP-noncompetitive allosteric inhibition.
| Endpoint | Reported result | Reference |
|---|---|---|
| Preactivated p-MEK1 phosphorylating ERK2 | IC50 290 nM; PD0325901: 110 nM | [1] |
| Preactivated p-MEK2 phosphorylating ERK2 | IC50 190 nM; PD0325901: 140 nM | [1] |
| B-Raf V600E/u-MEK1 and B-Raf V600E/u-MEK2 coupled ERK2 phosphorylation | IC50 3.5 nM (MEK1); 5.3 nM (MEK2); PD0325901: 4.1 and 3.6 nM, respectively | [1] |
| Truncated c-Raf/u-MEK1 and c-Raf/u-MEK2 coupled ERK2 phosphorylation | IC50 11 nM (MEK1); 7.9 nM (MEK2); PD0325901: 24 and 6.0 nM, respectively | [1] |
| B-Raf and c-Raf phosphorylation of MBP | IC50 >10,000 nM for both Raf isoforms; PD0325901 also >10,000 nM | [1] |
| ATP-varied MEK–ERK kinetics | qualitative ATP-noncompetitive allosteric inhibition | [1] |
Literature-Reported Treatment Conditions
- Treatment concentration
- IC50 concentration-response series; Fig 2D JTP-74057: 0, 0.125, 0.25 or 0.5 μM
- Exposure duration
- 15-min preincubation without ATP, then 20-min kinase reaction at 30°C
- Method
- Recombinant kinase assays; 10 μM ATP for Table 1 assays; ATP varied in Fig 2D
- Co-treatment
- PD0325901 and U0126 were separate comparator treatments.
- Reported limits
- Full IC50 titration range and solvent concentration not specified in the read kinase-assay methods. Coupled-assay IC50 is not a binding constant or treatment dose.
Methods and source locations
Compound reported in the paper: Trametinib; Compound label in the paper: JTP-74057
Evidence concerns the reported trametinib material. Solvate/salt equivalence and Adooq lot performance were not established.
Table 1, enzyme rows; Figure 2D and caption; Results Effects of JTP-74057 on enzyme activity; Methods Enzymatic kinase assays
Preactivated p-MEK1 phosphorylating ERK2: Radiolabeled ATP incorporation; ERK2 substrate or MBP direct-Raf control. Means of three independent experiments; no dispersion given in table. — Table 1; enzyme rows; means of three independent experiments
Preactivated p-MEK2 phosphorylating ERK2: Radiolabeled ATP incorporation; ERK2 substrate or MBP direct-Raf control. Means of three independent experiments; no dispersion given in table. — Table 1; enzyme rows; means of three independent experiments
B-Raf V600E/u-MEK1 and B-Raf V600E/u-MEK2 coupled ERK2 phosphorylation: Radiolabeled ATP incorporation; ERK2 substrate or MBP direct-Raf control. Means of three independent experiments; no dispersion given in table. — Table 1; enzyme rows; means of three independent experiments
Truncated c-Raf/u-MEK1 and c-Raf/u-MEK2 coupled ERK2 phosphorylation: Radiolabeled ATP incorporation; ERK2 substrate or MBP direct-Raf control. Means of three independent experiments; no dispersion given in table. — Table 1; enzyme rows; means of three independent experiments
B-Raf and c-Raf phosphorylation of MBP: Radiolabeled ATP incorporation; ERK2 substrate or MBP direct-Raf control. Means of three independent experiments; no dispersion given in table. — Table 1; enzyme rows; means of three independent experiments
ATP-varied MEK–ERK kinetics: Double-reciprocal analysis; no-inhibitor and PD0325901/U0126 comparator series; caption specifies means of two or three independent experiments. — Figure 2D/caption; Results Effects of JTP-74057 on enzyme activity